After an extensive investigation, the Federal Trade Commission on Wednesday cleared Pfizer Inc.’s acquisition of Wyeth, but required divestitures in the animal pharmaceutical market.

FTC staff conducted nearly 200 interviews and reviewed hundreds of thousands of pages of documents before concluding that the deal did not raise anti-competitive concerns in any human health product markets. But the commission did find overlap for animal products such as vaccines for cattle, dogs, cats and horses.